A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis
In patients with giant-cell arteritis, upadacitinib at a dose of 15 mg - but not 7.5 mg - with a 26-week glucocorticoid taper showed efficacy superior to that of placebo with a 52-week glucocorticoid taper. (Funded by AbbVie; SELECT-GCA ClinicalTrials.gov number, NCT03725202.).
Authors
- Wolfgang Schmidt (ORCID: https://orcid.org/0000-0001-7831-8738)
- Ivan Lagunes
- Ellen‐Margrethe Hauge (ORCID: https://orcid.org/0000-0003-2562-9174)
- Andrea Rubbert‐Roth (ORCID: https://orcid.org/0000-0002-9016-2833)
- Peter K. Wung
- Arathi R. Setty
- NADER A. KHALIDI (ORCID: https://orcid.org/0000-0002-8270-2617)
- Tomonori Ishii (ORCID: https://orcid.org/0000-0001-5361-5824)
- María C. Cid (ORCID: https://orcid.org/0000-0002-4730-0938)
- Helen Keen (ORCID: https://orcid.org/0000-0002-8469-2424)
- Christian Dejaco (ORCID: https://orcid.org/0000-0002-0173-0668)
- Daniël Blockmans (ORCID: https://orcid.org/0000-0001-9783-1780)
- Bernhard Hellmich (ORCID: https://orcid.org/0000-0002-8014-1801)
- Meng Liu (ORCID: https://orcid.org/0000-0002-6960-3163)
- Weihan Zhao (ORCID: https://orcid.org/0000-0002-9316-8181)
- Peter A. Merkel (ORCID: https://orcid.org/0000-0001-9284-7345)
- S. Penn
- A. Romero
Institutions
- The University of Western Australia (AU)
- Medical University of Graz (AT)
- University of St.Gallen (CH)
- Aarhus University (DK)
- Fiona Stanley Hospital (AU)
- Aarhus University Hospital (DK)
- AbbVie (United States) (US)
- Immanuel Krankenhaus (DE)
- Center for Rheumatology (US)
- St. Joseph’s Healthcare Hamilton (CA)
- Universitat de Barcelona (ES)
- University of Pennsylvania (US)
- University of Tübingen (DE)
- Tohoku Medical and Pharmaceutical University (JP)
- McMaster University (CA)
- KU Leuven (BE)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1056/nejmoa2413449
- Citations
- 57
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 86.55
Funders
- AbbVie